AstraZeneca thyroid cancer drug gets EU approval

By Admin
UK pharmaceutical manufacturer AstraZeneca has been given a boost by European drug regulators who have approved its vandetanib drug as a potential trea...

UK pharmaceutical manufacturer AstraZeneca has been given a boost by European drug regulators who have approved its vandetanib drug as a potential treatment for thyroid cancer.

Vandetanib, also sold and marketed under the brand name Caprelsa, has a turbulent past few years and AstraZeneca will no doubt breathe a sigh of relief at its approval.

The drug will treat medullary thyroid cancer (MTC) tumours which are not suitable for surgical removal and have spread to other areas of the body.

To read the latest edition of Healthcare Global, click here

Approval of the drug came after the regulators reviewed the Phase III clinical trial data, which revealed using Caprelsa reduces the risk of the disease progressing by 54 percent by preventing blood from flowing to tumours and inhibiting their growth.  

At the moment there are no approved treatments for MTC in Europe.

When Caprelsa first emerged on the pharmaceutical scene it was tipped to be a blockbuster drug and was estimated to be worth $1billion to the company.

However, the drug hit a stumbling block when, in clinical trials, it was unable to extend the lives of cancer sufferers.

Pharmaceutical industry experts are now predicting the drug will not prove to be a blockbuster for AstraZenca, as it is targeted at a niche market as MTC affects only four percent of thyroid cancer sufferers.

Forecasts published on Thomson Reuters Pharma have estimated in five years time, by 2016, sales of Caprelsa will reach $112million, a far cry from its original £1billion estimations.

Our magazine is now available on the iPad. Click here to download it.

Share

Featured Articles

Johnson & Johnson: Turning supplier spend into local support

Johnson & Johnson’s Global Supplier Diversity & Inclusion team is growing spending with social enterprises around the globe to expand its impact

Seasonal Affective Disorder’s impact on health & solutions

Dr Ravi Gill & Dr. Naomi Newman-Beinart discuss Seasonal Affective Disorder and its treatments, from vitamin D spray to light therapy

CGI teams up with Totalmobile for digital healthcare service

CGI is driving efficiency in healthcare. Hear from Helena Jochberger, at Manufacturing Digital LIVE, a free virtual event on Wednesday 6th December 2023

Deloitte: generative AI can improve access to healthcare

Technology & AI

Wipro & NVIDIA’s revolutionary healthcare uses generative AI

AI & ML

Healthtech platform CoverSelf extends seed round to US$8.2m

Technology & AI